April 6 (Reuters) – Neurocrine Biosciences will purchase uncommon illness drugmaker Soleno Therapeutics for $2.9 billion in money, the businesses stated on Monday, marking the neuroscience-focused drugmaker’s growth into metabolic problems.
Neurocrine has provided $53 per Soleno share held, which represents a premium of about 34% to inventory’s final shut.
Soleno shares, which had risen greater than 30% in premarket buying and selling after the Financial Times first reported the information, had been halted.
The deal provides Neurocrine entry to Vykat XR, the primary drug accredited within the U.S. to deal with hyperphagia related to Prader-Willi syndrome, a uncommon genetic dysfunction.
Hyperphagia, or emotions of intense and protracted starvation, is the hallmark symptom of Prader-Willi syndrome and might lead to extreme weight problems in addition to bodily, psychological and behavioural issues.
(Reporting by Gnaneshwar Rajan and Mariam Sunny in Bengaluru; Editing by Vijay Kishore and Sriraj Kalluvila)
